As a consequence of confidentiality agreements, the identities of the trial participants continue being undisclosed. Eli Lilly, the pharmaceutical corporation behind retatrutide, declined to comment on the protocols of its ongoing trials but said that patient protection is often a precedence.The value hasn't been declared as it continues to be in p